¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative risk ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative motion
    »ó´ë¿îµ¿
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • abortion ratio
    À¯»êºñ
  • age-dependency ratio
    ¿¬·ÉºÎ¾çºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • resource based relative value scale
    Áö¿ø±âÁØ»ó´ë°¡Ä¡
  • absolute risk
    Àý´ëÀ§Çè, Àý´ëÀ§Çèµµ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • acceptable risk
    Çã¿ëÀ§Çè, Çã¿ëÀ§Çèµµ
  • anesthetic risk
    ¸¶ÃëÀ§Çèµµ
  • attributable risk
    ±â¿©À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • explosion risk
    Æø¹ßÀ§Çèµµ
  • risk factor
    À§ÇèÀÎÀÚ
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • air pollution ratio
    ´ë±â¿À¿°·ü(ÊÙËô).
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î ³úô¼ö¾×/Ç÷û ºñ
  • albumin-globulin ratio =A£¯G r.
    ¾ËºÎ¹Î ±Û·ÎºÒ¸°ºñ.
  • albumin/globulin ratio
    ¾ËºÎ¹Î/±Û·ÎºÒ¸° ºñ
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • arm ratio
    µÎÆÈºñ(¡­Ýï).
  • gas exchange ratio
    °¡½º±³È¯ºñÀ²(ÎßüµÝï×Ë).
  • gyromagnetic ratio
    ȸÀü Àڱ⠺ñÀ²
  • heart lung ratio =HLR
    ½ÉÆó°è¼ö(ãýøËÌõâ¦), ½ÉÈä(°û)ºñ(ãýýØÎ¬Ýï).
  • hydrodynamic ratio
    ¼ö·ÂÇÐ(Àû) ºñÀ²
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • innervation ratio
    ½Å°æÁö¹èºñ(¡­Ýï).
  • inspiratory expiratory ratio
    ÈíÈ£±â´ëºñ.
  • phase ratio
    »óºñ(ßÓÝï).
  • primary sex ratio
    ÀÏÂ÷¼º ºñ(ÊÙËÛËÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hearing, relative
    »ó´ëÀû û°¨
  • radiation,relative biologic effectiveness(rbe)
    »ó´ëÀû(ºñ±³Àû)»ý¹°ÇÐÀûÈ¿°ú(ßÓÓßîÜ(ÝïÎòîÜßæÚªùÊîÜüùÍý)
  • relative accommodation
    »ó´ëÁ¶Àý(ÝïÎòðàï½).
  • relative acidosis
    »ó´ëÀû »êÁõ(ßÓÓßîÜß«ñø).
  • relative afferent pupillary defect
    »ó´ëÀû±¸½É¼ºµ¿°ø¿îµ¿Àå¾Ö
  • relative biologic effectiveness of radiation
    ¹æ»ç¼±ÀÇ»ó´ëÀû»ý¹°ÇÐÀûÈ¿°ú(Û¯ÞÒàÊ¡­ßÓÓßîÜßæÚªùÊîÜüùÍý)
  • relative biological effectiveness
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative biological effectiveness
    »ó´ëÀû »ý¹°ÇÐÀû È¿°ú(ßÓÓßîÜßæÚªùÊîÜüù
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£)
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • flux ratio method
    Çöô½º ºñÀ²¹ý(Ýï×ËÛö)
  • frictional ratio
    ¸¶Âûºñ(ؤóÍÝï)
  • G + C/A + T ratio
    G + C/A + T ºñ(Ýï)
  • gyromagnetic ratio
    ÀÚ±âȸÀü ºñ(í¸Ñ¨üÞï®Ýï)
  • ratio
    ºñÀ²(Ýï×Ë)
  • induction ratio
    À¯µµºñ(ë¯ÓôÝï)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • L/S ratio
    L/S À²(ëÏ)
  • mass-action ratio
    Áú·®ÀÛ¿ëÀ²(òõÕáíÂéÄëÒ)
  • nucleo-cytoplasmic ratio
    ÇÙ(ú·).¼¼Æ÷Áú(á¬øàòõ) ºñ(Ýï)
  • packing ratio
    ÆäÅ·À²(ëÒ)
  • polarity ratio
    ±Ø¼º ºñÀ²(пàõÝï×Ë)
  • P:O ratio
    P/O ºñ
  • protein efficiency ratio
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ(üù×ËÝï)
  • protein efficiency ratio method
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ¹ý(üù×ËÝïÛö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
RO radiation oncology; radiation output; ratio of; relative odds; renal osteodystrophy; reverse osmosis...
A/G ratio Albumin/Globulin ratio; ¾ËºÎ¹Î´ë ±Û·ÎºÒ¸°ÀÇ ºñÀ²
S/D ratio Systolic / Diastolic ratio
C/N carbon/nitrogen [ratio]; carrier/ noise [ratio]
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ARIC Atherosclerosis Risk In Communities
AR Attributable Risk
BRFSS Behavioral Risk Factor Surveillance System
CVRF Cardiovascular risk factor
CRIB Clinical Risk Index for Babies
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • innervation ratio
    ½Å°æ Áö¹è ºñ
  • magnetization transfer ratio
    ÀÚÈ­ Àü´Þ ºñÀ²
  • mercuryalloy ratio
    ¼öÀº Çձݺñ
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • optimal ratio
    ÃÖÀûºñ
  • optimum ratio
    ÃÖÀûºñ
  • phase ratio
    »óºñ
  • ratio
    ºñ
    ¾î¶² ¹°Áú ¶Ç´Â ½ÇüÀÇ ¾çÀ» ´Ù¸¥ °Í°ú ºñ±³ÇÑ Ç¥ÇöÀ¸·Î¼­, º¸Åë ÇÑÂÊÀÇ ¾çÀ» ´Ù¸¥ÂÊÀÇ ¾çÀ¸·Î ³ª´« °ªÀ¸·Î Ç¥½ÃÇÑ´Ù.
  • sex ratio
    ¼ººñ
  • signal-to-noise ratio
    ½ÅÈ£-ÀâÀ½ºñ, ½ÅÈ£´ë ¼ÒÀ½ ºñÀ²
  • train of four ratio
    »ç¿¬¼Ó ¹ÝÀÀºñ
  • unharmonic ratio
    ºñÁ¶È­ºñ
  • uptake ratio
    ¼·ÃëÀ²
  • ventilation perfusion ratio
    ȯ±âÀ²
  • W/P ratio
    È¥¼öºñ
    ¼®°íÀÇ ¿¬È­¿¡ »ç¿ëµÇ´Â ¹°ÀÇ ¾ç°ú ¼®°í ºÐ¸»ÀÇ ¹«°Ô ºñ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
risk factor <statistics> A clearly defined occurrence or characteristic that has been associated with the increased rate of a subsequently occurring disease.
(14 Oct 1997)
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
risk management The process of minimizing risk to an organization by developing systems to identify and analyze potential hazards to prevent accidents, injuries, and other adverse occurrences, and by attempting to handle events and incidents which do occur in such a manner that their effect and cost are minimised. Effective risk management has its greatest benefits in application to insurance in order to avert or minimise financial liability.
(12 Dec 1998)
risk of recurrence In medical genetics, the chance that a genetic (inherited) disease present in a family will recur in that family. The concept in general medicine means the chance that an illness we come back again.
(12 Dec 1998)
risk patient Patient who is at risk, because of his/her behaviour or because of the type of person he/she is.
(18 Nov 1997)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
empiric risk The chance that a disease will occur in a family based upon experience (past history, medical records, etc.) rather than theory.
(12 Dec 1998)
absolute terminal innervation ratio The number of motor endplates divided by the number of terminal axons related to them.
(05 Mar 2000)
accommodative convergence-accommodation ratio The amount of convergence (measured in prism diopters of convergence) divided by the amount of accommodation (measured in diopters) required to direct both eyes upon an object.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • elderly dependency ratio
    ³ë·ÉÀÚ(ÇÇ)ºÎ¾ç·ü
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
  • ratio
    ºñ;ºñÀ²
  • respiratory quotient (ratio)
    È£Èí·ü;È£Èíºñ(³»¹ñ´Â ź»ê°¡½ºÀÇ ¾ç°ú ¿ÜºÎ·ÎºÎÅÍ Èí¼öÇÏ´Â »ê¼Ò·®°úÀÇ ºñ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á